Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.
Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.
Integra LifeSciences Holdings Corp ownership disclosure: Paradigm Capital Management, Inc. reports 4,012,698 shares of Common Stock, representing 5.16% of the class as of 03/31/2026. The filing states these securities are owned by advisory clients and Paradigm has sole voting and dispositive power over these shares.
HILL BARBARA B reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that director Barbara B. Hill received two stock awards of the company’s Common Stock on May 7, 2026. She was granted 17,700 shares and 6,638 shares at a price of $0.00 per share as equity compensation. Following these awards, she directly owns 151,191 shares, and an additional 36,350 shares are held indirectly by a trust.
Integra LifeSciences director Keith Bradley reported routine equity compensation and related tax withholding. He received 17,700 Restricted Stock Units (RSUs) on May 7, 2026 under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan, with each RSU representing a right to one share of common stock and vesting in full on the one-year anniversary of the grant date. To cover tax obligations, 882 shares of common stock were withheld at $13.92 per share. Following these transactions, Bradley directly holds 88,254 shares of Integra common stock.
Clay Shaundra reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Shaundra Clay received a grant of 17,700 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of IART common stock under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the May 7, 2026 grant date. Clay elected to defer receipt of the underlying shares, which will be delivered in a single lump sum in the calendar year following the year her service on the Board ends, unless she elected a later year.
GRAVES JEFFREY A reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Jeffrey A. Graves received a grant of 17,700 Restricted Stock Units (RSUs). The award was made on May 7, 2026 under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, at a grant price of $0.00 per unit.
Each RSU represents a contingent right to receive one share of Integra LifeSciences common stock, so the grant covers 17,700 underlying shares. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Following this grant, Graves holds 17,700 RSUs directly.
Lo Renee Wonlai reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Renee Wonlai Lo received a grant of 17,700 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of IART common stock. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026, and this award brings her reported RSU holdings to 17,700 units.
SCHADE CHRISTIAN S reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP director Christian S. Schade received a grant of 17,700 restricted stock units (RSUs) tied to the company’s common stock. The award was made at no cash cost under Integra’s Fifth Amended and Restated 2003 Equity Incentive Plan.
The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Schade elected to defer delivery of the underlying shares until a lump-sum payment is made in the calendar year after his service on the Board ends, or a later year he elected. Following this grant, he holds 17,700 RSUs directly from this award.
Integra LifeSciences Holdings Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 7, 2026. Stockholders approved Amendment No. 3 to the Fifth Amended and Restated 2003 Equity Incentive Plan, increasing the number of common shares available for equity awards by 3,550,000 shares.
All director nominees were elected, each receiving over 62 million votes in favor, with broker non-votes of 3,918,311 for each nominee. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 fiscal year and approved, on an advisory and non-binding basis, the compensation of the named executive officers.
Integra LifeSciences delivered higher revenue but remained unprofitable for the quarter ended March 31, 2026. Total revenue rose to $391.9 million from $382.7 million a year earlier, led by Specialty Surgery at $283.1 million and Tissue Reconstruction at $108.8 million.
The company swung to operating income of $11.5 million from an operating loss of $15.5 million, helped by lower cost of goods sold and tighter operating expenses. Net loss narrowed significantly to $4.6 million, or $(0.06) per share, compared with a net loss of $25.3 million, or $(0.33) per share.
Cash generation improved, with operating cash flow of $9.8 million versus an outflow of $11.3 million in the prior-year quarter. The balance sheet showed cash and cash equivalents of $236.8 million, short‑term investments of $28.7 million, and total debt of about $1.87 billion. The company also recorded an $18.7 million IEEPA tariff refund receivable, providing a benefit to current-year costs.
Integra LifeSciences delivered higher revenue but remained unprofitable for the quarter ended March 31, 2026. Total revenue rose to $391.9 million from $382.7 million a year earlier, led by Specialty Surgery at $283.1 million and Tissue Reconstruction at $108.8 million.
The company swung to operating income of $11.5 million from an operating loss of $15.5 million, helped by lower cost of goods sold and tighter operating expenses. Net loss narrowed significantly to $4.6 million, or $(0.06) per share, compared with a net loss of $25.3 million, or $(0.33) per share.
Cash generation improved, with operating cash flow of $9.8 million versus an outflow of $11.3 million in the prior-year quarter. The balance sheet showed cash and cash equivalents of $236.8 million, short‑term investments of $28.7 million, and total debt of about $1.87 billion. The company also recorded an $18.7 million IEEPA tariff refund receivable, providing a benefit to current-year costs.
Integra LifeSciences announced a major leadership transition, appointing longtime director and current chairman Stuart M. Essig as president and chief executive officer effective May 1, 2026, succeeding Mojdeh Poul, who departed as CEO and board member on April 30, 2026.
Under his new employment agreement, Mr. Essig will receive a $1,075,000 base salary, a target annual bonus equal to 125% of salary, and one-time equity awards of $4 million in restricted stock units and $4 million in stock options, each vesting over three years. The agreement also provides for severance of up to 2.99 times salary plus target bonus, continued health coverage, and accelerated equity vesting in certain terminations and change in control scenarios.
The company entered into a separation agreement with Ms. Poul that includes a cash payment of $566,526 and reimbursement of up to $25,000 in legal fees, along with previously disclosed severance benefits. Integra also created a new chief commercial officer role, appointing Michael McBreen, who will receive a $660,000 salary, a 90% target bonus, and a $1 million promotion equity award, with broader commercial responsibilities designed to sharpen customer and market focus.
Integra LifeSciences announced a major leadership transition, appointing longtime director and current chairman Stuart M. Essig as president and chief executive officer effective May 1, 2026, succeeding Mojdeh Poul, who departed as CEO and board member on April 30, 2026.
Under his new employment agreement, Mr. Essig will receive a $1,075,000 base salary, a target annual bonus equal to 125% of salary, and one-time equity awards of $4 million in restricted stock units and $4 million in stock options, each vesting over three years. The agreement also provides for severance of up to 2.99 times salary plus target bonus, continued health coverage, and accelerated equity vesting in certain terminations and change in control scenarios.
The company entered into a separation agreement with Ms. Poul that includes a cash payment of $566,526 and reimbursement of up to $25,000 in legal fees, along with previously disclosed severance benefits. Integra also created a new chief commercial officer role, appointing Michael McBreen, who will receive a $660,000 salary, a 90% target bonus, and a $1 million promotion equity award, with broader commercial responsibilities designed to sharpen customer and market focus.